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ABSTRACT
Background
Human immunodeficiency virus (HIV) sero-prevalence rate during pregnancy was 26% in
2009 in Gauteng. HIV exposure is associated with high morbidity and mortality in infants.
Few studies have assessed the effect of HIV exposure on morbidity and mortality in very low
birth weight (VLBW) infants.
Aim
To determine the infant characteristics at birth, morbidity during hospital stay and mortality
at hospital discharge of VLBW infants according to maternal HIV status.
Methods
This was a retrospective cross sectional descriptive study. Hospital records of VLBW infants
admitted at the Chris Hani Baragwanath Academic Hospital, Division of Neonatology from
1st January 2011 to 30th June 2011 were reviewed. Data were collected in an Excel spread
sheet and imported to STATA version 12 for analysis.
Results
302 hospital records of VLBW infants admitted from January to June 2011 were retrieved
and reviewed. About a third (34.1%) of VLBW infants were born to mothers who were HIV
positive. There were more babies who weighed <1000 grams in the HIV-exposed infants
compared to HIV-unexposed infants (p-0.001). HIV exposed infants had a smaller head
circumference (p-0.003), a shorter body length (p-0.006) and significantly more severe grades
of IVH (p <0.001) compared to HIV unexposed infants. The overall mortality rate in VLBW
infants was 27%, with HIV exposed infants having a mortality rate of 38.6% compared to
21% in the HIV-negative infants (p-0.002). Multivariate analysis showed that the main
predictor of mortality was birth weight (p<0.001).
Conclusion
Though on univariate analysis maternal HIV status was associated with mortality in VLBW
infants, this effect was not found on multivariate analysis. Therefore the final conclusion
from this study is that maternal HIV status has no independent effect on outcomes to hospital
discharge in VLBW infants. Birth weight was the predictor of survival in VLBW infants.
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1CHAPTER 1: INTRODUCTION
Human immunodeficiency virus (HIV) is a major cause of infant and childhood morbidity
and mortality in sub-Saharan Africa1.  The antenatal HIV sero-prevalence in Gauteng
Province was estimated to be 26% in 20092, implying that more than one quarter of infants
born in the province are HIV-exposed 2. Pregnancies in which HIV features as a complicating
factor are at increased risk for premature delivery1,3,4, and other life-threatening outcomes
(including infection) in mothers and exposed infants3,5. There are limited studies which
explore the extent to which HIV exposure impacts on outcomes in very low birth weight
(VLBW) infants. The aim of this study was to determine the characteristics, morbidity and
mortality in HIV-exposed compared to HIV-unexposed VLBW infants at Chris Hani
Baragwanath Academic Hospital.
2CHAPTER 2: LITERATURE REVIEW
2.1 HIV infection and pregnancy
Over thirty years have elapsed since the first case of HIV infection was reported6. During this
period, HIV has evolved from a fatal condition to a manageable chronic disease7,8. In 2012,
35.3 million people were living with HIV; 3.3 million of whom were children with more than
90% of them from Sub-Saharan Africa6. Although the number of new paediatric infections
has reduced significantly from 350,000 in 2010 to 260,000 in 2012; more than 90% of these
infections are through vertical transmission with over 95% of new paediatric infections
occurring in Sub-Saharan Africa7,8,9.
HIV infection can be transmitted through the following routes; unprotected sexual intercourse
with an infected partner, injection or transfusion of contaminated blood or blood products
(infection, through artificial insemination, skin grafts and organ transplants is also possible),
sharing unsterilized injection equipment that has been previously used by someone who is
infected, maternal-fetal transmission (during pregnancy, at birth, and through breastfeeding).
In Sub-Saharan Africa, most infections among adults are through sexual contact while over
95% of pediatric infections are through vertical transmission from mother to child during
pregnancy, delivery or breastfeeding period6,7,10. Without any intervention to prevent the
transmission of HIV from mother to child, 15-30% of infants will get infected in utero or
during delivery. An additional 10-15% of infections will occur during breastfeeding
period7,9,10.
Biologically, women are at higher risk of contracting HIV during sexual intercourse with an
HIV infected male partner11. In addition, HIV prevalence among women of reproductive age
has been linked to several socioeconomic and cultural factors12. Low financial income makes
3women vulnerable by contributing to trans generational relationship and sex for money
practices6,12. Migration within or across borders separates families; thereby making multiple
concurrent partners common practices12,13. In Southern Africa where men leave their wives
and spend several years in mines has been known to be one of the key factors in high HIV
prevalence in South Africa and other Southern African countries13. Furthermore, in recent
times there has been a surge of migration of women from rural to urban area of South Africa
looking for jobs13. Social conditions in townships where these women live fueled by poverty
further contribute their vulnerability in acquiring HIV infection13. Cultural practices that
promote inequality between women and men make women vulnerable to acquiring HIV. In
additional, sexual violence especially rape has been known to contribute to increase
prevalence among women6,12,13.
The HIV epidemic among adolescents and adults has stabilized in several African countries
including South Africa6. Despite effort in preventing mother to child transmission of HIV,
there is still a lot that needs to be done. Most especially to ensure pregnant women access
antenatal care services during which interventions can be offered to those who are found to
be HIV infected. In addition, there is need for male partner involvement considering the high
number of sero-discordant relationships and the number of women who sero-convert during
pregnancy6,14. With success in prevention of mother to child transmission of HIV, the number
of children with HIV infection has been reduced, but the number of children who are exposed
to HIV will remain high as long as the prevalence of HIV infection in women at reproductive
ages remains high.
42.2 Perinatal outcomes in HIV infected Mothers
In developing countries one of the infections that is at epidemic level is HIV infection. HIV
infected pregnant women are at increased risk for their own health and that of the foetus/new
born infants14. Among women of reproductive health, HIV is a recognized leading cause of
death14,15. In Sub-Saharan Africa, maternal mortality has continued to rise proportional to
HIV prevalence in ANC attendees in recent years15,16,17. There are several hypotheses on how
HIV and pregnancy interact. Whatever the case, there is immunological progression of the
disease during pregnancy period and introduction of antiretroviral therapy before or during
pregnancy has been shown to contribute positively to pregnancy outcomes16,17,18.
In different studies, the excess risk of pregnancy-related mortality attributable to HIV among
women who were HIV-infected (attributable risk) ranged from 174 per 100 000 pregnant
women in South Africa19 to 28386 per 100 000 pregnant women in Zimbabwe20. In a meta-
analysis, Calvert et al found that overall, the pooled attributable risk from all the studies was
994 per 100 000 women (95% CI 677–1310)21, 22, 23.
Different studies have given variable outcomes for infants born to HIV infected women. In a
study in Botswana, Reitter et al, found that 36.5% of deliveries of HIV exposed infants were
preterm24. Many studies in sub-Saharan African countries have shown that infants born to
HIV-infected women have a significantly increased risk of low birth weight, preterm birth,
neonatal mortality and infant mortality25,26,27. Kim and colleagues found that maternal HIV
was associated with pregnancy loss and perinatal mortality28. They reported that maternal
HIV disease affected infant health and survival directly via the risk of HIV transmission and
indirectly via low birth weight and prematurity28. The effect of intrauterine HIV infection in
5the infant was apparent by 70 days but excess neonatal mortality was primarily attributed to
low birth weight and preterm birth independent of infant HIV status28.
Global rates of mother-to-child HIV-1 transmission vary from region to region, depending on
the infrastructures available to prevent vertical transmission of HIV; estimates range from 14
to 48% in the absence of appropriate prevention of mother-to-child HIV transmission
(PMTCT) programmes5,28,29,30. In non-breastfeeding populations, in the era before optimised
PMTCT activities, the risk of perinatal HIV transmission was in the region of 15–25%29,30.
The variation in the rate of transmission may be due to maternal viral loads (mothers with
elevated viral loads tend to transmit virus more effectively to their infants through the
placental barrier in utero, or during the birth process)30, or to the viral type (certain clades of
HIV are more virulent, and more easily transmissible)29,31,32. Mock et al observed that one-
third of infants infected in utero were VLBW deliveries, and report that VLBW is associated
with in utero transmission of HIV32.  Maternal HIV infection has been shown to be associated
with   a   number   of   adverse perinatal outcomes, including preterm delivery and
VLBW32,33. Brocklehurst and French, in a systematic review, reported that adverse perinatal
outcomes related to maternal HIV infection include: IUGR, VLBW, and preterm delivery33.
Laar et al found that maternal HIV infection status was associated with a VLBW prevalence
of 23% among neonates born to HIV-positive women, compared to 14% among those born to
HIV-negative women34. Comparatively, pre-term delivery was higher among HIV positive
mothers (24% versus 14%)34.  In a Cochrane review, Sturt et al demonstrated that VLBW
was associated with use of antiretroviral therapy (ART) in HIV infected women35.
Furthermore, Ekouevi et al conducted an observational study in a breast feeding population in
the Ivory Coast, to determine the efficacy of highly active ART compared to a short-course
prophylactic ART regimen in preventing vertical transmission of HIV from mothers to their
6infants36.  The risk of giving birth to a VLBW infant was significantly higher in the prolonged
ART arm (31/139; 22%) compared to the short course ART arm (21/170; 12%), (Relative
Risk [RR] 1.81; 95% Confidence Interval [CI], 1.09 - 3.0)36. Similarly, Tonwe-Gold et al,
deriving their data from the Ivory Coast cohort mentioned above, demonstrated that VLBW
occurred significantly more frequently in the ART arm (26%) than in the short course ART
group (9%), (RR 2.17; 95% CI 1.23 - 3.81)37.
2.3 Morbidities in infants born to HIV positive mothers
HIV is a major cause of infant and childhood morbidity and mortality especially in Sub-
Saharan Africa38. HIV exposed infant is an infant born of HIV infected mother38,39. In a
study, comparing HIV exposed to HIV unexposed infants, there was a 1.5-fold higher
prevalence of anemia at 1 month of age among HIV exposed infants (20%, 32 of 160)
compared with infants born to HIV-negative women (13.8%, 71 of 514)40.
HIV co-infection with other infections are common in women living with HIV40,41. This
increases the risk of such infections in HIV exposed infants e.g. syphilis, TB, and
CMV41,42,43. Effect of HIV exposure on immune function in the foetus could result to
immunosuppression, therefore increased risk of infection at birth, and during hospital stay
(nosocomial infections). Immune response has been demonstrated in HIV exposed infants
who are not infected. CD8+ immune responses to HIV-1 Env, Gag, and Nef proteins are
present in peripheral blood of these infants shortly after birth44. De Maria and Rowland-Jones
and colleagues demonstrated in separate studies that HIV-1-specific CD8+ IFN-ү responses
have been detected in the peripheral blood of 25% of exposed uninfected infants between 15
to 50 months of age as well as in an uninfected infant using virus-specific stimulation45, 46. In
addition, Legrand et al, showed that HIV exposed uninfected infants had higher levels of
7CD4+, CD25+, CD1272 T-regulatory cells in neonatal cord blood, decreased T-cells
activation levels thereby leading to increased risk of infection47. Further, they found that,
there was augmented HIV-1 Gag, CD8+, IFN-c, CD4+ and IL-2 immune response in
exposed-uninfected neonatal cord blood upon the removal of T-regulatory cells neonatal cord
blood47. VLBW infants are more likely to be preterm, therefore at risk of developing NEC.
HIV exposure has been implicated in development of NEC40, 41, 42.
2.4 Infant mortality and HIV exposure
In Sub-Saharan Africa, HIV infection accounts for a significant mortality and morbidity in
childhood especially in countries with a generalized epidemic43. Naniche et al, showed in a
study in Mozambique that overall infant mortality was 2.3-fold higher in babies born to HIV-
positive women than those born to HIV-negative women (p-0.002)40. Considering the timing
of deaths, it was with post-neonatal deaths that differences were noted between HIV-exposed
and unexposed infants. Infants born of HIV-positive mothers had a higher post neonatal
mortality rate (7.8%, 15 of 193) than those born to HIV-negative mothers (1.9%, 12 of 623)
(p < 0.001)40. However, Monebenimp et al found mortality to be similar between HIV
exposed and HIV unexposed infants in a case control study in Yaoundé Cameroon48.
2.5. Morbidity and mortality among VLBW infants
By definition, very low birth weight infants are those who have a birth weight less than 1500
grams3,49. Very low birth weight can be caused by preterm birth, intrauterine growth
restriction, or a combination of both49,50. Ngoc, et al, reported that preterm delivery
contributed up to 61% of children with low birth weight in six developing countries51.
Considering determinants of low birth weight, small for gestational age and preterm delivery
in Indonesia, Sebayang et al found constitutional, demographic and psychosocial factors,
8toxic exposure, maternal nutrition and obstetric history and maternal morbidity during and
prior to pregnancy to be key determinants52. Infants who weigh 2000-2499 g at birth have a
four-fold higher risk of neonatal death than those who weigh 2500-2999 g, and a ten-fold
higher risk than those weighing 3000 - 3499g35,53.
VLBW infants are more susceptible to hypoglycaemia and to birth asphyxia33. In a
substantial number of studies they suffered more diarrhoea and pneumonia for a few months
after birth, explaining in part why LBW is also a risk factor for post neonatal death1,33,54.
During the first weeks of life, wasted, LBW new-borns experienced more morbidity whereas
stunted new-borns were more likely to die during this time 35,36.
Very low birth weight infants are prone to disease conditions ranging from infections to
metabolic imbalance39. Infections associated with VLBW can be bacterial, fungal or viral. Up
to a quarter of VLBW suffer from nosocomial infections with rates higher in lower weights
and younger gestational age54,55. Staphylococcus species account for more than half of
bacterial nosocomial infections55. Sepsis is associated with increased rate of intraventricular
hemorrhage, periventricular leukomalacia, neurodevelopmental impairment, chronic lung
disease, increased number of days on ventilator support54,55,56. These conditions occur as a
result of the immature organs and immunological system of the VLBW infants55,56.
In terms of fungal infections, they account for major cause of morbidity among VLBW and
preterm infants. Aydemir et al demonstrated in a randomized clinical trial that prophylactic
treatment of fungal infection among VLBW was associated with reduced mortality57. Viral
infections can be acquired during intra-uterine period or peri-natally. In a systematic review
and meta-analysis, Lanzieri et al demonstrated that VLBW infants are at increased risk of
9perinatally acquired cytomegalovirus infection which leads to hepatopathy, respiratory
distress syndrome, sepsis like syndrome, low white cell count, thrombocytopenia42.
In a meta-analysis describing mortality among infants in East Africa, preterm delivery and
low birth weight accounted for 52% of deaths58. In an audit of disease and mortality in
neonatal ward in Johannesburg hospital, Ballot and colleagues reported extreme mulitorgan
immaturity, hyaline membrane disease (HMD), asphyxia, necrotizing enterocolitis (NEC),
nosocomial sepsis, septicaemia, congenital infection, intraventricular haemorrhage (IVH),
congenital abnormality, pulmonary haemorrhage as leading causes of deaths among
VLBW59. In a study in Iran, Nayeri reported a mortality rate of 33% in their ward. Some of
the factors associated with mortality were respiratory distress syndrome, neurological
complications, intraventricular hemorrhage, need for resuscitation at birth, low Apgar score
and need for a ventilator59.
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CHAPTER 3: METHODOLOGY
3.1 Aim and Objectives
3.1.1 Aim
The aim was to determine the infant characteristics at birth, morbidity during hospital stay
and mortality at hospital discharge of VLBW infants according to maternal HIV status.
3.1.2 Objectives
1. To describe demographic characteristics, clinical presentation and laboratory findings
at birth of HIV-exposed and unexposed VLBW infants.
2. To determine the mortality rate in HIV-exposed VLBW infants.
3. To determine mortality rate in HIV-unexposed VLBW infants.
4. To compare the mortality rates between HIV exposed and unexposed VLBW infants.
5. To determine predictors of mortality in VLBW infants.
3.2 Methods
3.2.1 Study design
This was a retrospective cross sectional descriptive study.
3.2.2 Site of study
The study was carried out at Chris Hani Baragwanath Academic Hospital (CHBAH)
Neonatal Unit. CHBAH is a tertiary health institution located in Soweto, Johannesburg in
South Africa. The neonatal unit is made up of four wards, neonatal intensive care unit (level 3
nursery); transitional care unit or high care (level 2 nursery); ward 66 (a combination of level
1 and 2 nursery), and ward 40 (kangaroo mother care unit – level 1). The neonatal unit had
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120 authorized beds but 160 usable beds (12 – NICU, 43- High care, 80- Ward 66, and 25 –
KMC) during the period studied.
3.2.3 Study population
The hospital conducts about 22 000 live births per year, of which 3-5% were estimated to be
VLBW (660 - 1100 infants). The study population was made up of all VLBW infants (infants
born with a weight less than 1500 g) who survived and were admitted to the Neonatal Unit
from 1st January to 30 June 2011.
3.2.4 Sample size
The primary outcome I focussed on was mortality rate. Assuming that the mortality rate in
VLBW infants at CHBAH was 25% with a margin of error of 5% and confidence level of
95%, we needed to have a sample size of 245 VLBW infants. In order to accommodate for
charts with missing outcome (mortality) I decided to enrol about 300 VLBW infants which
required that I collected charts over a time period of 6 months (1st January to 30 June 2011).
3.2.5 Data collection
Variables were then extracted from patients’ files and entered into an Excel spread sheet.
Each file was given a code (numbered in order of folder review) and this code was linked to
the data entered into the Excel sheet and the study participant anonymously so as to maintain
confidentiality of study participants. A special form was designed to extract data from the
hospital records. The data collected included maternal and infant demographic characteristics,
maternal HIV-related laboratory results, clinical presentation and diagnosis at birth,
laboratory findings in those who had blood tests done and outcomes (comorbidities and
survival) to hospital discharge (data collection sheet in Appendix 1).
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3.2.6 Data management and analysis
Data checking was done on all categorical and continuous variables captured for values that
were not within plausible range and attempt was also made to check for missing values to
authenticate that these values were actually missing. Data was collected in an Excel spread
sheet and imported to STATA version 12 and Epi info version 7 for analysis.
Data was described using means and standard deviation for parametric continuous variables,
and medians and ranges for non-parametric continuous variables. Categorical variables were
described using percentages. Comparison of continuous measurements was done with a
Student t-test where measurements were normal distributed and Mann-Whitney test where
measurements were not normal distributed. Comparisons of categorical variables
measurement were performed using a chi-square test. Statistical significance was set at 0.05.
Univariate analysis was used to compare different variables between HIV-exposed and
unexposed infants. Multivariable logistic regression was used to detect predictors of mortality
in VLBW infants.
3.2.7 Ethics
Data collected was treated with confidentiality and anonymously using a coding system. The
latter was a serial number allocation made of 4 digits preceded by the first alphabet of the
ward to which the infant was first admitted to the CHBAH Neonatal Unit (for example if the
first patient is from NICU the code was N0001, if from TC or High care the code was T0001,
and if from Ward66 the code was W0001). Each file selected was given a code/identity
number that links the file to the Excel data sheet. Only the principal investigator had access to
the linked file. Application for ethics approval was made and obtained from the Human
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Ethics Research Committee (HREC) of the University of the Witwatersrand (Appendix 2).
Institutional approvals were obtained from the Chief Executive Officer of CHBAH, by
application to the institution’s Medical Advisory Committee (Appendix 3). As this was a
retrospective record review, informed consent was not required from parents or caregivers.
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CHAPTER 4: RESULTS
There were 546 VLBW infants admitted in the neonatal wards of CHBAH from 1st January to
June 2011. The first 306 patient’s records found were analyzed, 4 of these records did not
have maternal HIV results, therefore were excluded. In total 302 VLBW infants had maternal
HIV results and outcome recorded and therefore were included and analyzed for this research
report.
4.1 Maternal characteristics
Out of the 302 infants included in this study, 103(34.1%) were born to mothers who were
HIV positive (HIV-exposed). Maternal age ranged from 16 to 43 years with the median age
of 26 years. Twelve (3.9%) women were aged less than 18 years with ten of them being HIV
negative and two of them being HIV positive (p-0.1935). Mothers who were HIV positive
were significantly older than HIV negative mothers, with a median age of 29 compared to 24
years (p<0.001) in HIV-negative mothers as shown in Table 1. Most mothers (72.5%) had
more than 1 previous pregnancy with more HIV positive mothers having more than 1
previous pregnancy than HIV negative mothers (p<0.001). Eighty three percent of mothers
attended antenatal care, and 51% delivered by caesarean section. There were no statistically
significant differences in number of mothers who attended antenatal clinic during pregnancy,
and those who delivered by caesarean section between HIV positive and HIV negative
women (p>0.05). Among the 103 mothers who were HIV positive, 67 (65%) had recorded
CD4 counts. The mean CD4 count was 323.4 (±186.3) cells/mm3, with 59.7% of them having
a CD4 count <350 cells/mm3. Seventy nine mothers were on antiretroviral drugs, with 38
(48%) of them receiving HAART and the rest getting ARVs for PMTCT.
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Table 4.1: Characteristics of mothers of very low birth weight infants admitted at CHBAH
over the 6 month period
Variable Total
(N=302)
HIV-Positive
(N=103)
HIV-Negative
(N=199)
p-value
Median Maternal Age
- Mothers <18 year old
26 (16-43)
12
29 (16-42)
10 (83%)
24 (16-43)
2 (17%)
<0.001
0.1935
Gravidity**
1
≥2
76 (27.1%)
205 (72.9%)
10 (10.8%)
83 (89.2%)
66 (35.1%)
122 (64.9%)
<0.001
Antenatal Care***
Yes
No
225 (83.3%)
45 (16.7%)
70 (81.4%)
16 (18.6%)
155 (84.2%)
29 (15.8%)
0.5591
Mode of delivery****
Vaginal
Abdominal
134 (48.6%)
142 (51.4%)
41 (45.1%)
50 (54.9%)
93 (50.3%)
92 (49.7%)
0.4151
Note:
**Ten HIV positive and eleven HIV negative women did not have records of their gravidity
***Seventeen HIV positive and fifteen HIV negative women did not have records of antenatal booking status.
****Twelve HIV positive and fourteen HIV negative women did not have records of mode of delivery
4.2. Infants demographics and clinical characteristics of the study population
Table 2 shows the infant characteristics and clinical profile of the study population (for both
HIV exposed and unexposed babies). Overall, almost all the infants were born before 36
weeks gestational age. There was no significant difference between HIV exposed and HIV
unexposed infants in terms of gestational age (p-0.224). Fifty four percent of infants were
females. About gender, there was no statistically significant difference between the HIV
exposed and unexposed infants.
The median birth weight was 1220 grams. There were more babies with birth weight less than
1000 grams in the HIV exposed infants compared to HIV-unexposed (p-0.001). The mean
head circumference and length at birth were 27.5±2.3 and 37.5±3.9 cm, respectively. HIV
exposed infants had statistically significant smaller head circumference (p-0.003) and shorter
length (p-0.006) at birth than HIV unexposed infants.
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The median Apgar scores at 1 and 5 minutes were 7 and 9 respectively. There were more
infants with Apgar score <7 at 1 minute (p-0.015) and at 5 minutes (p-0.030) in the HIV
exposed infants. Sixty three percent of VLBW infants were exclusively breast fed. The HIV
exposed infants were more likely to be exclusively formula fed (63.1%) than HIV unexposed
infants 30.5% (p<0.001).
Table 4.2: Demographic and clinical characteristics of very low birth weight infants admitted
at CHBAH over a 6 month period.
Variables Total
(n=302)
HIV
exposed
n = 103
HIV unexposed
n = 199
p-value
Mean Gestational age (weeks)*
<28
28-32
>32
63 (21)
196 (65.3)
41 (13.7)
29.4 ±2.9
28 (27.7)
60 (59.4)
13 (12.9)
29.82 ± 2.7
35 (17.6)
136 (68.3)
28 (14.1)
0.224
Female 164 (54.5) 59 (57.8) 105 ( 52.8) 0.400
Birth Weight**
Number weighing <1000 grams
Number weighing 1000-1499 grams
88 (29.2)
213 (70.8)
42 (41.2)
60 (58.8)
46 (23.1)
153 (76.9)
0.001
Body length at birth (cm) 37.5 ± 3.9 36.6± 4.0 38.0 ± 3.9 0.006
Head Circumference at birth (cm) 27.5 ± 2.3 26.9± 2.4 27.7 ±2.2 0.003
Apgar score at 1 minute***
0-6
7-10
122 (45.7)
145 (54.3)
50(55.0)
41(45.0)
72 (40.9)
104 (59.1)
0.015
Apgar score at 5 minutes****
0-6
7-10
38 (14.9)
218 (85.1)
18 (20.7)
69 (79.3)
20 (13.4)
149 (86.6)
0.030
Note:
* Two HIV exposed infants did not have records of gestational age
** One HIV exposed infant did not have record for birth weight
*** Twelve HIV exposed and twenty three HIV unexposed infants did not have records of Apgar score at one minute
****Sixteen HIV exposed infants and 30 HIV unexposed infants did not have records of Apgar score at five minutes.
4.3. Laboratory profile of study population (HIV exposed and HIV unexposed babies)
Table 4.3 describes clinical and clinical profile of HIV exposed and HIV unexposed infants.
Eleven (3.4%) infant had congenital abnormalities. There was no statistical difference in
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prevalence of congenital abnormalities between HIV-exposed and HIV-unexposed infants (p-
0.631).
The commonest diagnosis on admission was respiratory distress syndrome (RDS) 220
(72.8%), followed by a combination of RDS and congenital pneumonia 78/281 (25.9%) and
congenital pneumonia 4 (1.3%). There was no statistically significant difference between
HIV exposed and unexposed infants in type of diagnoses on admission (p-0.250).
The mean white blood cell count, and platelet count at birth were 10.3 x 109cells/mm3, and
198 x 109cells/mm3 respectively. There were no significant differences between HIV exposed
and HIV unexposed infants in these full blood count parameters (p-0.734). The mean C-
reactive protein (CRP) was 3.1 with more than 95% of sick infants at birth having a CRP of
less than ten. There were no differences between HIV exposed and HIV unexposed infants in
CRP levels. There was no statistical difference between infants with positive blood cultures at
birth in the sick HIV-exposed infants (7.1%) compared to the sick HIV-unexposed infants
(4.9%), p-0.27.
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Table 4.3: Clinical Presentation and Laboratory findings at birth in VLBW infants
Variables Total
N=302 (%)
HIV exposed
n=103 (%)
HIV unexposed
n=199 (%)
p-value
Congenital abnormalities*
No
Yes
286 (96.6)
11 (3.4)
98 (97.0)
3 (3.0)
188 (95.9)
8 (4.1)
0.631
Admission diagnosis
Respiratory Distress Syndrome
Congenital Pneumonia
Both of the above
220 (72.8)
4 (1.3)
78 (25.9)
79 (35.9)
0 (0.0)
24 (30.8)
141 (70.9)
4 (2.0)
54 (27.1)
0.250
White blood cell count (x 109/L)**
No. with Wcc <9 x 109/ L
No. with Wcc 9-30 x 109 /L
No. with Wcc >30 x 109 /L
136 (91.3)
3 (2.0)
10 (6.7)
47 (82.5)
0 (0.0)
10 (17.5)
89 (96.7)
3 (3.3)
0 (0.0)
0.734
Platelets count (x 109/L)***
No. with platelets <150 x 109 /L
No. with platelets ≥150 x 109 /L
75 (28.2)
191 (71.8)
27 (29.0)
66 (71.0)
48 (27.7)
125 (72.3)
0.350
CRP****
No. with CRP <10 mg/dL
No. with CRP ≥10 mg/dL
241(94.5)
14 (5.5)
80 (94.1)
5 (5.9)
161(94.7)
9 (5.3)
0.934
Blood culture at birth *****+
Negative
Positive
Contaminants
255 (90.7)
16 (5.7)
10 (3.6)
84 (85.8)
7 (7.1)
7 (7.1)
171 (93.5)
9 (4.9)
3 (1.6)
0.270
Note:
* Two HIV exposed infants and three HIV unexposed infants did not have record under congenital anomalies.
** Forty six HIV exposed and one hundred and seven HIV unexposed did not have record of white blood cells count measurement.
*** Ten HIV exposed and twenty six HIV unexposed did not have records of platelets count.
****Eighteen HIV exposed and twenty nine HIV unexposed infants did not have records of CRP results.
***** Five HIV exposed and sixteen HIV unexposed infants did not have records of blood culture at birth.
+ Six patients had Group B Streptococcus, ten patients had other microorganisms and ten had contaminants of Bacillus, CNS and
corynebacterium.
4.4. Morbidity and mortality in VLBW infants
Table 4.4 shows distribution of co-morbidities and outcomes in VLBW infants. Other than
the diagnoses made at the time of admission, the morbidities that were recorded in the infant
records were suspected infections, necrotizing enterocolitis (NEC) and intraventricular
infections. Overall 62.7% of VLBW infant had episodes of suspected nosocomial infections
with more than half having more than one episode of suspected nosocomial infection during
their stay in the hospital. There was no statistically significant difference between HIV
exposed and HIV unexposed infants in number of episodes of infection (p-0.536).
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Though 19.7% of VLBW infants had a working diagnosis of suspected NEC during their stay
in hospital, only 3.6% had Stage 2 and/ or Stage 3 NEC. There were no differences in
incidence of NEC or severe NEC between HIV-exposed and unexposed VLBW infants (17.2
vs 21.2%, p-0.465). Of the 63 infants who had records of cranial ultrasound having been done
to exclude IVH, about two thirds (70%) had abnormal findings (Grade I-IV IVH) with HIV
exposed infants having significantly more severe grades of IVH compared to HIV unexposed
infants (p <0.001).
In terms of survival to hospital discharge of the 302 charts reviewed, only 296 had
documented outcome at discharge. 216/296 (73.0%) infants were discharged while 80/296
(27.0%) infants died. HIV exposed infants were significantly at higher risk of dying than HIV
unexposed infants (p<0.001).
Table 4.4: Morbidities and survival in VLBW infants
Variables Total HIV exposed HIV unexposed p-value
Nosocomial sepsis
No
Yes
101 (37.1)
171 (62.9)
32 (36.8)
55 (63.2)
69 (37.3)
116 (62.7)
0.144
Number of episodes of
nosocomial sepsis
1-3
>3
133 (53.2)
38 (15.2)
44 (55.0)
11 (13.7)
89 (52.4)
27 (15.9)
0.536
Necrotizing enterocolitis
- No
- Stage 1
- Stage 2
- Stage 3
240 (80.3)
49 (16.1)
7 (2.3)
4 (1.3 )
84 (82.4)
13 (12.3)
2 (2.0)
3 (2.9)
156 (78.8)
36 (18.2
5 (2.5)
1 (0.5)
0.464
Intraventricular haemorrhage
Normal
Grade 1-2
Grade 3
Grade 4
17  (27.0)
26 (41.3)
11 (17.5)
9 (14.3)
4 (14.3)
8 (28.6)
9 (32.1)
7 (25.0)
13 (37.1)
18 (51.4)
2 (5.7)
2 (5.7)
<0.001
Alive at hospital discharge
Yes
No
216 (73.0)
80 (27.0)
62 (62.4)
39 (38.6)
154 (79.0)
41(21.0)
0.012
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4.5. Predictors of mortality in VLBW infants
Table 4.5 shows the analysis of predictors of mortality among all the VLBWI in the study. In
the univariate analysis the factors associated with mortality were maternal HIV status (p-
0.001), infant birth weight (p<0.001), gestational age (p<0.001), and Apgar score at 1
(p<0.001) and 5 minutes (p<0.001), and presence of congenital abnormalities (p-0.006). In a
multivariate analysis, the only predictor of mortality was infant birth weight (p<0.001).
Congenital abnormalities had a trend toward significance (p-0.063).
Table 4.5: Predictors of mortality in all VLBWI
Variables Survivors
(n=216)
Non-survivors
(n= 80)
Univariate
analysis
Multivariate
analysis
p-value p-value
Mean maternal age in years (±SD) 27.0 ± 6.7 27.7 ± 7.1 0.452 -
Median maternal gravidity* 2 (1-8) 2 (1-8) 0.809 -
Percent attended antenatal care 85.79% 78.57% 0.158 -
Maternal HIV status positive 28.70% 48.75% 0.002 0.342
Percent delivered abdominal 45.81% 52.86% 0.308 -
Mean birth weight in grams (±SD) 1216 ± 175 930 ± 232 <0.001 <0.001
Mean gestational age in weeks (±SD) 30.4 ± 2.5 27.8 ± 2.7 <0.001 0.106
Percent with male sex 43.52% 51.85% 0.124 -
Median Apgar score 1 minute* 7 (1-10) 5 (1-9) <0.001 0.559
Median Apgar score 5 minutes* 9 (1-10) 7 (1-9) <0.001 0.103
Percent with congenital abnormalities 1.9% 8.6% 0.012 0.063
* - Numbers in parenthesis are Ranges
SD – Standard Deviation
Table 4.6 shows analysis for predictors of mortality among VLBW infants who were HIV-
unexposed. In univariate analysis the factors associated with mortality in the HIV-unexposed
infants were birth weight (p<0.001), gestational age (p<0.001), Apgar score at 1 minute
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(p<0.001), and 5 minutes (p<0.001), and congenital abnormality (p-0.043). In a multivariate
analysis, predictor of mortality among this subgroup was infant birth weight (p<0.001).
Table 4.6: Predictors of mortality in HIV-unexposed VLBW infants
Variables Survivors
(n= 154)
Non- Survivors
(n=41)
Univariate
analysis
Multivariate
analysis
p-value p-value
Mean maternal age in years (±SD) 26.3 ± 6.9 24.9 ± 6.5 0.268 -
Median maternal gravidity* 2 (1-7) 2 (1-5) 0.558 -
Percent attended antenatal care 85.42% 81.08% 0.610 -
Percent delivered abdominal 46.58% 61.11% 0.138 -
Mean birth weight in grams (±SD) 1218 ± 181 984 ± 264 <0.001 <0.001
Mean gestational age in weeks (±SD) 30.3 ± 2.5 28.0 ± 3.0 <0.001 0.993
Percent with male sex 44.81% 56.10% 0.198 -
Median Apgar score at 1 minute* 8 (1-10) 6 (2-9) <0.001 0.275
Median Apgar score at 5 minutes* 9 (0-10) 7 (4-9) <0.001 0.164
Percent with congenital abnormalities 2.65% 9.76% 0.043 0.480
* - Numbers in parenthesis are Ranges
SD – Standard Deviation
Table 4.7 shows analysis of predictors of mortality among HIV exposed VLBW infants.
Univariate analysis revealed that factors that were associated with increased risk for mortality
in HIV exposed VLBW infants were birth weight (p<0.001), gestational age (p<0.001),
Apgar score at 1 minute (p<0.001), and 5 minutes (p<0.001), diagnosis at birth (p<0.010) and
congenital abnormalities which tends toward statistically significant value (p-0.052). In
multivariate analysis, the predictors of mortality in this subgroup included infant birth weight
(p-0.002) and gestational age (p-0.018).
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Table 4.7: Predictors of mortality among the HIV-exposed VLBWI
Variables Survivors
(n= 62 )
Non-
Survivors
(n= 39 )
Univariate
analysis
Multivariate
analysis
p-value p-value
Mean maternal age in years (±SD) 29.0 ± 5.9 30.9 ± 6.4 0.143 -
Median maternal gravidity* 3 (1-8) 2 (1-8) 0.517 -
Percent attended antenatal care 86.79% 75.00% 0.240 -
Percent delivered abdominal 43.86% 45.45% 0.528 -
Mean birth weight in grams (±SD) 1212 ± 161 884 ± 176 <0.001 0.002
Mean gestational age in weeks (±SD) 30.5 ± 2.5 27.5 ± 2.5 <0.001 0.018
Percent male sex 40.32% 46.15% 0.353 -
Median Apgar score 1 minute* 7 (1-10) 5 (4-9) <0.001 0.637
Median Apgar score 5 minutes* 9 (6-10) 7 (2-10) <0.001 0.520
Percent with congenital abnormalities 0 7.89% 0.052 -
* - Number in parenthesis are Ranges,
SD – Standard deviation
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CHAPTER 5: DISCUSSION
This study was carried out to determine clinical diagnosis, laboratory findings at birth,
morbidity during hospital stay and outcome (discharge or dead) among HIV unexposed and
HIV exposed very low birth weight infants admitted at CHBAH. Charts of very low birth
weight infants were reviewed and relevant variables extracted, entered into excel data base,
cleaned and uploaded into Stata and Epi info for analysis.
The major findings of this study were as follows about a third of mothers giving birth to
VLBW infants were HIV positive, with about 60% of those with recorded CD4 counts having
counts <350; and HIV positive mothers were more likely to give birth to ELBW infants. HIV
exposed infants had lower Apgar scores at 1 and 5 minutes, and those who had cranial sonar
were more likely to have severe IVHs. The mortality rate was higher in HIV exposed infants
and the predictor of mortality was birth weight in all VLBW irrespective of maternal HIV
status. However among HIV exposed infants gestational age significantly predicted mortality
in addition to birth weight.
World Health Organisation states that in order to improve pregnancy outcomes, women must
start antenatal care early in the first trimester and have at least four ANC visits in a low risk
pregnancy7. It is important to note that women whose records were reviewed in our study,
almost half attended their first ANC in the first trimester. South Africa is known with high
ANC attendance which contributes significantly to the quality of care60. HIV prevalence
among ANC attendees in South Africa especially in Gauteng has remained high over the
years and our study population demonstrated this high prevalence although there is a slight
drop compared to findings by Ballot and colleagues in the similar setting such as Charlotte
Maxeke academic hospital38. The high prevalence in such settings may be explained by the
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fact that being a referral hospital, most of the time other lower health institution send patients
with complications among whom are HIV infected pregnant women.
Recent South African PMTCT guidelines call for the classification of advanced
immunological HIV status to be CD4<350 cells/ml for which pregnant women must be
initiated on ART for their own health 61,62. These guidelines were implemented after the
period of this study, therefore a large number of mothers were not on HAART. Two thirds of
records of the participants, who tested HIV positive, had a CD4 count less than 350cells/ml.
So the change in PMTCT guidelines implies that more patients will be put on HAART,
therefore future studies will be able to look at the effect of HAART on morbidity and
mortality in VLBW62,63.
Several factors are known to contribute to the delivery of very low birth weight infants63,64.
Of importance is prematurity which in some cases is coupled with intra-uterine growth
restriction63,64. Of the infants reviewed in this study none were term, the peak age being
between 28 and 32 weeks gestational age. Findings in this study suggest that infections play
an important role as a large number of babies were diagnosed with congenital pneumonia at
birth.
HIV exposure through the mother was found to be one of the factors associated with higher
mortality35,37. This calls for more research to find out why HIV exposed infants who were
known not to be HIV infected died more than HIV unexposed. It may be useful to assess the
functional response of this immature immune system when it developed in the HIV
environment37. Ballot and colleagues demonstrated that the survival rate of VLBW was
70.5% in Charlotte Maxeke Johannesburg Academic hospital in 2006/2007. In this patient
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population, 36% of infants were HIV exposed although the testing rate among mothers was
only 69%38.
While comparing HIV exposed and HIV unexposed infants, of all the characteristics, there
was no significant difference between the two groups of infants except the final outcome of
mortality where HIV exposed infants were one and half time more likely to die compared to
HIV unexposed. Despite the fact that close to one third of HIV women were on ART at the
time of review, there was no difference in weight among the infants. It has been reported that
intrauterine exposure to ARV especially AZT is associated with VLBW35,36,64. In our study
there was no documentation of various regimens of women and the timing of initiation of
ART as it relates to pregnancy.
The implication of this study shows that HIV exposure increases the risk of death among
VLBW infants. Key factors associated with mortality are birth weight and gestational age.
Considering the high HIV prevalence among ANC attendees, it is important to put in place
systems that will retain HIV positive pregnant women in care with appropriate documentation
to facilitate monitoring. There may be need to carry out a prospective study to understand
causes of mortality among VLBW infants. Unavailability of quality data in the clinical
records on important variables such as HIV status, DNA PCR results, CD4 and antiretroviral
regimen calls for concern on the quality of documentation.
This study had several limitations. I used retrospective data which were not initially designed
for research purpose. As such there were several data elements missing in the records. In
addition, this was a cross sectional study which was unable to give the overall picture of the
management of VLBW infants. Furthermore, this study was carried out only in one hospital
which, being a tertiary institution makes the findings not generalizable.
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In conclusion, HIV prevalence among women of reproductive age remains high. This calls
for more strategies in improving primary prevention which is the first pillar of comprehensive
prevention of mother to child transmission of HIV. Though on univariate analysis maternal
HIV status was associated with mortality in VLBW infants, this effect was not found on
multivariate analysis. Therefore the final conclusion from this study is that birth weight is the
main predictor of survival in VLBW infants, not the maternal HIV status.
27
References:
1 Vinay K, Ritu P, Gayatri B, Sanjeevani K, editors. Management of pediatric HIV: a
physician’s handbook. Narayan Peth: Mudra, 2009.
2 Health Systems Trust. Health Indicators: recently updated indicators. Durban: HST,
2011. Available: http://indicators.hst.org.za/healthstats/314/data [Accessed 25
October 2011]
3 Barbara JS, Robert MK. The fetus and the neonatal infant, non-infectious disorders:
overview of mortality and morbidity. In: Berman RE, Kliegman RM, Jenson HB,
editors. Nelson textbook of paediatrics. Philadelphia: Elsevier Science, 2004:520-522.
4 Mackay CA, Ballot DE, Cooper PA. Growth of a cohort of very low birth weight
infants in Johannesburg, South Africa. BMC Paediatrics 2011;11:50.
5 The African Network for care of children affected by AIDS. Introduction. In:
Tindyebwa D, Kayita J, Musoke P, Ely B, Nduati R, Coovadia H, editors. Handbook
on Paediatric AIDS in Africa. Kampala: ANECCA, 2004: 11-14
6 UNAIDS. Global report. New York: UNAIDS, 2013. Available:
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/
gr2013/UNAIDS_Global_Report_2013_en.pdf [Accessed 22 February 2014]
7 World Health Organization. PMTCT Strategic Vision 2010-2015: Preventing mother-
to-child transmission of HIV to reach the UNGASS and Millenium Development
Goals. 2010.
8 Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early
antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;
359:2233–2244.
9 Wettstein C, Mugglin C, Egger M, Blaser N, Salazar L, Estill J, et al. Missed
Opportunities to Prevent Mother-to-Child-Transmission in sub-Saharan Africa:
Systematic Review and Meta-Analysis. AIDS. 2012;26: 2361–2373.
28
10 Kinabo, J. Seasonal variation of birth weight distribution in Morogoro, Tanzania. East
African Medical Journal, 1993; 70:752–755.
11 Rubbert-Roth A, Behrens G, Ostrowski. Pathogenesis of HIV-1 infection. In:
Hoffmann C, Rockstroh JR, Kamps BS, edotors. HIV 2010: Berlin: Schrὄders
Agentur, 2010: 33-40.
12 Dunkle KL, Stephenson R, Karita E, Chombe E, Kayitenkore K, Vwalika et al. New
heterosexually transmitted HIV infections in married or cohabiting couples in urban
Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008;371:2183–
91.
13 Halperin DT, Epstein H. Why is HIV prevalence so severe in Southern Africa? South
Afr J HIV Med 2007;26:19–25.
14 World Health Organization. Women and health. Geneva, Switzerland: World Health
Organization; 2009.
15 French R, Brocklehurst P. The effect of pregnancy on survival in women infected
with HIV a systematic review of the literature and meta-analysis. BJOG 1998;
105:827–835.
16 Minkoff HL, Henderson C, Mendez H, Gail MH, Holman S, Willoughby A, et al.
Pregnancy outcomes among mothers infected with human immunodeficiency virus
and uninfected control subjects. Am J Obstet Gynecol 1990; 163:1598–1604.
17 Leroy V, Ladner J, Nyiraziraje M, De Clercq A, Bazubagira A, Van de Perre P, et al.
Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992–
1994. Pregnancy and HIV Study Group. AIDS 1998; 12:643–650.
18 Mattar R, Amed AM, Lindsey PC, Sass N, Daher S. Preeclampsia and HIV infection.
Eur J Obstet Gynecol Reprod Biol 2004; 117:240–241.
29
19 Khan M, Pillay T, Moodley JM, Connolly CA. Maternal mortality associated with
tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15:1857–1863.
20 Ticconi C, Mapfumo M, Dorrucci M, Naha N, Tarira E, Pietropolli A, et al. Effect of
maternal HIV and malaria infection on pregnancy and perinatal outcome in
Zimbabwe. J Acquir Immune Defic Syndr 2003; 34:289–294.
21 Calvert C, Ronsmans C The contribution of HIV to pregnancy-related mortality: a
systematic review and meta-analysis. AIDS 2013, 27:1631–1639.
22 Maiques-Montesinos V, Cervera-Sanchez J, Bellver-Pradas J, Abad-Carrascosa A,
Serra-Serra V. Post cesarean section morbidity in HIV-positive women. Acta Obstet
Gynecol Scand 1999; 78:789–792.
23 Zvandasara P, Hargrove JW, Ntozini R, Chidawanyika H, Mutasa K, Iliff PJ, et al.
Mortality and morbidity among postpartum HIV-positive and HIV-negative women in
Zimbabwe: risk factors, causes, and impact of single-dose postpartum vitamin A
supplementation. J Acquir Immune Defic Syndr 2006; 43:107–116.
24 Reitter A, Stücker AU,  Buxmann H, Herrmann E,  Haberl AE, Schlößer R, et al.
Prenatal Ultrasound Screening for Fetal Anomalies and Outcomes in High-Risk
Pregnancies due to Maternal HIV Infection: A Retrospective Study. Infectious
Diseases in Obstetrics and Gynecology 2013, 208482;10. Available:
http://dx.doi.org/10.1155/2013/208482. [Accessed 21 February 2014]
25 Chi BH, Wang L, Read JS, Taha TE, Sinkala M, Brown ER, et al. Predictors of
stillbirth in Sub-Saharan Africa. Obstet Gynecol 2007; 110:989–997.
26 Braddick MR, Kreiss JK, Embree JE, Datta P. Impact of maternal HIV infection on
obstetrical and early neonatal outcome. AIDS 1990; 4:1001–1005.
27 Castetbon K, Ladner J, Leroy V, Chauliac M, Karita E, De Clercq A, et al. Pregnancy,
Study Group HIV: Low birth weight in infants born to African HIV-infected women:
30
relationship with maternal body weight during pregnancy. J Trop Pediatrics 1999,
45:152–157.
28 Kim HY, Kasonde P, Mwiya M, Thea DM, Kankasa C, Sinkala M, et al. Pregnancy
loss and role of infant HIV status on perinatal mortality among HIV-infected women.
BMC Pediatrics 2012;12:138-151.
29 John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus
type 1. Epidemiol Rev 1996; 18:149–157.
30 The Working Group on Mother-to-Child Transmission of HIV: Rates of mother-to-
child transmission of HIV 1 in Africa, America, and Europe: Results from 13
Perinatal Studies. J Acquire Immune Deficiency Syndrome Hum Retrovirol 1995;
8:506–510.
31 Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al.
Maternal viral load, zidovudine treatment, and the risk of transmission of human
immunodeficiency virus type 1 from mother to infant. NEngl J Med 1996;335:1621–
1629.
32 Mock PA, Shaffer N, Bhadrakom C, Siriwasin W, Chotpitayasunondh T, Chearskul S,
et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok,
Thailand. AIDS 1999;13:2-4 .
33 Brocklehurst P, French R. The association between maternal HIV infection and
perinatal outcome: a systematic review of the literature and meta-analysis. Br J.
Obstet. Gynaecol 1998; 105:836-848.
34 Laar AK, Ampofo W, Tuakli JM, NorgbeGK,Quayi IA. Preterm delivery and low
birth weight among neonates born to HIV-positive and HIV-negative Ghanaian
women. Journal of public health and Epidemiology 2001; 2:224-237.
31
35 Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV
infection in ART-eligible pregnant women (Review): The Cochrane Collaboration
2010; 3:8440. Available: http://www.thecochranelibrary.com. [Accessed10th
September 2011]
36 Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, et al.
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy
outcomes in Abidjan, Cote d’Ivoire. AIDS, 2008; 22:1815–20.
37 Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al.
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission
in West Africa: evaluation of a two-tiered approach. PLoS Med, 2007;4: e257.
38 Ballot DE, Chirwa TF, Cooper PA. Determinants of survival in very low birth weight
neonates in a public sector hospital in Johannesburg. BMC Pediatric 2010;10:30.
39 Blanc A, Wardlaw T. Monitoring low birth weight: an evaluation of international
estimates and an updated estimation procedure. Bulletin of the World Health
Organization, 2005, 83:178–185.
40 Naniche D, Bardají A, Lahuerta M, Berenguera A, Mandomando I, Sanz S et al.
Impact of Maternal Human Immunodeficiency Virus Infection on Birth Outcomes and
Infant Survival in Rural Mozambique. Am. J. Trop. Med. Hyg 2009;80(5): 870–876.
Available: http://www.ajtmh.org/content/80/5/870.full.pdf+html [Accessed 22
February 2013]
41 Gupta A, Khandekar M, Thakar M, Bollinger RC, Bhosale R, Karmarker A, et al.
Maternal tuberculosis: A risk factor for mother-to-child transmission of Human
Immunodeficiency Virus. JID 2011;203:358-363.
32
42 Lanzieri TM, Dollard SC, Josephson CD, Schmid , Bialek SR. Breast Milk–Acquired
Cytomegalovirus Infection and Disease in VLBW and Premature Infants. Pediatrics
2013;131:1937–1945.
43 Pillay K, Colvin M, Williams R, Coovadia HM. Impact of HIV-1 infection in South
Africa. Arch Dis Child 2001; 85: 50-51
44 Cheynier R, Langlade-Demoyen P, Marescot MR, Blanche S, Blondin G, Wain-
Hobson S, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children
born to human immunodeficiency virus-1-infected mothers. Eur J Immunol
1992;22:2211–2217.
45 De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type
1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to
HIV-1-infected mothers. J Infect Dis 1994; 170:1296–1299.
46 Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, et al.
HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.
Lancet 1993; 341: 860–861.
47 Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. Strong
HIV-1-Specific T Cell Responses in HIV-1-Exposed Uninfected Infants and Neonates
Revealed after Regulatory T Cell Removal. PLoS ONE 2006; 1(1): e102. Available:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762312/pdf/pone.0000102.pdf
Accessed 27 February 2014.
48 Monebenimp F, Ella ND, Zoung-Kany Bissek AC, Chelo D, Tetanye E. HIV
exposure and related newborn morbidity and mortality in the University Teaching
Hospital of Yaoundé, Cameroon. The Pan African Medical Journal - 2011; 8:43.
49 WHO/UNICEF. Low birth weight: country, regional and global estimates. New York,
United Nations Children’s Fund and World Health Organization, 2004. Available:
33
http://www.who.int/reproductivehealth/publications/low_birthweight/low_birthweight
_estimates.pdf. [Accessed 15 September 2011]
50 World Health Organisation. International Classification of Diseases. 10th Revision.
Geneva, World Health Organization, 2004. Accessed at
http://www.who.int/classifications/icd/en/ [Accessed 15 September 2011].
51 Ngoc NTN, Merialdi M, Abdel-Aleem H, Carroli G, Purwar M, Navaleta N, et al.
Causes of stillbirths and early neonatal deaths: data from 7993 pregnancies in six
developing countries. Bulletin of the World Health Organization 2006; 84:699–705.
52 Sebayang SK, Dibley MJ, Kelly PJ, Shankar AV, Anuraj, Shankar H. Determinants of
low birth weight, small for gestational age and preterm births in Lombok, Indonesia:
analyses of the birth weight cohort of the SUMMIT trial. Tropical Medicine and
International Health 2012; 17(8) 938–950.
53 Young S, Murray K, Mwesigwa J, Natureeba P, Osterbauer B, Achan J, et al.
Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural
Ugandan women receiving combination antiretroviral therapy. PLoS ONE 7(8).
Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413694. [Accessed 23
December 2013]
54 Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent
staphylococcal infection in very low birth weight infants. Cochrane Database of
Systematic Reviews 2009;2:006449. Available: http://www. onlinelibrary.wiley.com
/doi/10.1002/14651858.CD006449.pub2/pdf. [Accessed 23 December 2013]
55 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-
onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal
Research Network. Pediatrics 2002;110:285–91.
34
56 Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al.
Neurodevelopmental and growth impairment among extremely low-birth-weight
infants with neonatal infection. Journal of the American Medical Association 2004;
292:2357–65.
57 Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al.
Randomised controlled trial of prophylactic fluconazole versus nystatin for the
prevention of fungal colonisation and invasive fungal infection in very low birth
weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F164–F168.
58 Marchant T, Willey B, Katz J, Clarke S, Kariuki S, Kuile F. Neonatal Mortality Risk
Associated with Preterm Birth in East Africa, Adjusted by Weight for Gestational
Age: Individual Participant Level Meta-Analysis. PLoS Med 2012 9(8): e1001292.
Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419185/ [Accessed 23
December 2013]
59 Nayeri F, Dalili H, Nili F, Amini E, Ardehali A, Mansoori BK et al. Risk Factors for
Neonatal Mortality Among Very Low Birth Weight Neonates. Acta Medica Iranica,
2013; 51(5): 297-302.
60 Solarin I, Black V. “They Told Me to Come Back”: Women’s antenatal Care Booking
experience in inner-city Johannesburg. Maternal Child Health J. 2013; 17(2): 359-
367. Available: http://dx.doc.org/10.1007%2Fs10995-1012-1019-6 [Accessed 24
March 2013]
61 Goga AE, Dinh TH, Jackson DJ for the SAPMTCTE study group. Evaluation of the
Effectiveness of the National Prevention of Mother-to-Child Transmission (PMTCT)
Programme Measured at Six Weeks Postpartum in South Africa. South African
Medical Research Council, National Department of Health of South Africa and
PEPFAR/US Centers for Disease Control and Prevention; 2010. Report No.: 40-42.
35
Available: http://www.doh.gov.za/docs/reports/2012/pmtcteffectiveness.pdf.
[Accessed 24 March 2013]
62 The Department of Health republic of South Africa. The South African Antiretroviral
Guidelines 2013: PMTCT guidelines: Revised 13 March 2013. Version 0.2 PP 8-10.
63 United Nations Children’s Fund and World Health Organization, Low Birth weight:
Country, regional and global estimates. UNICEF, New York, 2004.
64 Kramer MS., ‘Determinants of Low Birth Weight: Methodological assessment and
meta-analysis’, Bulletin of the World Health Organization, 1987; 65(5):663–737.
36
Appendix 1: Data collection form
1 2 3 4
Study Number
DOB
1 = Female, 2 = Male
Birth weight (g)
Birth head circumference (cm)
Birth length (cm)
APGAR Score at 1, 5, 10 minutes
Gestational Age (weeks)
Admission diagnosis: Respiratory distress at birth, 1 = Hyaline membrane disease, 2 = Congenital pneumonia,3 = Other (specify)
Ever Ventilated in NICU? 0 = No, 1 = Yes
Date of NICU admission
Date of NICU discharge
Length of mechanical ventilation (days)
Surfactant administered? 0 = No, 1 = Yes
Number of doses of surfactant
Congenital abnormality: 0 = No, 1 = Yes
Type of congenital abnormality
STORCH infection: 0 = Not investigated for, 1 =Yes, 2 = No
Type of STORCH infection
Congenital sepsis/pneumonia
0 = No, 1 = Yes, 2 = Suspected
Birth blood culture result
Birth WCC
Birth Plt count
Nosocomial sepsis: 0 = No, 1 = Yes
Number of courses of antibiotics during hospital stay
Date of NVP start
Date of HIV PCR test
HIV PCR Result: 0 = Negative, 1 = Positive
Date of start of cotrimoxazole prophylaxis
Discharge Diagnoses: 1 = HMD, 2 = Congenital pneumonia,3 = Other (specify)
Outcome: 1 = Discharged, 2 = Died, 3 = Refused hospital treatment
Discharge weight (g)
Discharge head circumference (cm)
Discharge length (cm)
Mother’s hospital number (for purposes of retrieval of results)
Maternal HIV status: 0 = Negative, 1 = Positive
Maternal CD4 count
Date Maternal CD4 Count
Maternal Viral Load
Feeding choice: 1 = Exclusive breastfeeding, 2 = Exclusive formula feeding, 3 = Mixed feeding
Maternal PMTCT: 0 = No, 1 = Yes, 2 = Not applicable
Maternal ART (for HIV-infected mother only): 0 = No, 1 = Yes
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